CSL adding scalable stem cell gene therapy tech in $91m Calimmune buy – BioPharma-Reporter.com
BioPharma-Reporter.com |
CSL adding scalable stem cell gene therapy tech in $91m Calimmune buy
BioPharma-Reporter.com According to spokeswoman Natalie de Vane, the acquisition is the first step into the cell and gene therapy space for CSL with the addition of an ex vivo hematopoietic stem cell (HSC) gene therapy candidate and R&D facilities in Pasadena, California … |
